George Church on the frontline of genetics once again!
Category: genetics – Page 524
“Cancer is a disease of ageing,” Lin, geneticist and president of the Rare Genomics Institute, told the audience at WIRED2016. The World Health Organisation estimates there are about 14 million new cases of cancer every year, and predicts that figure will double by 2050. Currently, eight million people are killed every year by the disease.
By combining early intervention with an understanding of cancer genomics, however, mankind could be on the cusp of fighting cancer effectively and at scale. “We are at the intersection of three of the most exciting revolutions in cancer therapy,” Lin said.
2 November 2016. Two companies partnering with Auburn University developed a synthetic virus to find and destroy tumor cells in a type of bone cancer in dogs. Financial and intellectual property aspects of the agreement between synthetic gene company Gen9 in Cambridge, Massachusetts, design systems developer Autodesk Inc. in San Rafael, California, and Auburn University College of Veterinary Medicine in Alabama were not disclosed.
The research team created a synthetic version of canine adenovirus type 2, or CAV2, a virus usually associated with hepatitis in dogs. In this case, the synthetic CAV-2 virus is designed as an oncolytic virus that finds and attacks cancer cells, while leaving healthy cells and tissue intact. The genome in the organism is believed to be the longest in a functional virus synthesized for cancer research, with about 34,000 base pairs of nucleic acids. The human genome, by comparison, has about 3 billion base pairs.
The technology provided by Gen9 in this project makes it possible to eventually produce synthetic therapeutic viruses tailored for specific patients. Gen9 offers customized gene synthesis and is developing a library of synthesized proteins and antibodies. One of the 4 year-old company’s founders is George Church, a geneticist at Harvard Medical School and serial entrepreneur. In August 2016, as reported in Science & Enterprise, Church and colleagues, including those from Gen9, developed a synthetic E. coli bacteria genome with redundant DNA components removed.
When the future of genetic engineering arrived on Sebastian Cocioba’s doorstep, it was affixed to the back of a postcard from Austria with a little bit of packing tape.
Cocioba is a 25-year-old college dropout whose primary interest is tinkering with plant genetics in a lab he cobbled together from eBay. The lab is located in the spare bedroom of his parent’s lavish apartment in Long Island City, across the river from Manhattan. A few months ago, an internet friend from an online bio-hacking forum had sent him the lab’s latest addition: attached to that postcard was Crispr-Cas9.
Bioquark Inc. (www.bioquark.com) Interview in MoneyWeek
Read whole story: http://moneyweek.com/who-wants-to-live-forever/
Why compliance exist.
Gingko Bioworks launched their new laboratory last month—an automated “factory” that mass-produces genetically modified organisms. The organism company’s tagline is “Biology By Design,” and it aims to deliver just that in their second foundry, which is equipped with numerous robots that mash together huge batches of genes to churn out new and exotic lifeforms […] Gingko is ambitiously working through the complexities of biology and genetics to create these experimental organisms. The company boasts of a design-build-test cycle: gene-enzyme mixes designed from the company’s scientific database is put together in a hundred different ways, and the “mashup” that services a client’s needs best is accepted as the new organism’s genetic profile. Their new liquid-handling robots like the Echo 525 make large-scale experimentation possible. (READ MORE)

Today I’m announcing a $100M commitment to Kernel in an effort to enhance human intelligence and reimagine our future. Unlocking our brain is the most significant and consequential opportunity in history — and it’s time sensitive.
We’re starting to identify the mechanisms underlying neural code and make them programmable. Our biology and genetics have become increasingly programmable; our neural code is next in line. Programming our neural code will enable us to author ourselves and our existence in ways that were previously unimaginable.
I started Kernel in 2016 (read more at the Washington Post) to build the world’s first neural prosthetic for human intelligence enhancement. The investment I’m making in Kernel today will expedite the development of this prosthetic and similarly transformative neurotechnologies.